---
title: "Immunic raises USD 200 million in private placement, with potential for up to USD 200 million more. Funds to support Phase 3 trials and transition to commercial-stage company."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275895038.md"
description: "An initial sum of $200 million has been received upfront, with the possibility of an additional $200 million in proceeds. This funding is anticipated to cover the costs associated with finalizing the Phase 3 ENSURE trials for relapsing multiple sclerosis, commencing the Phase 3 trial for primary progressive multiple sclerosis, and facilitating the transition into the next phase of the project."
datetime: "2026-02-13T11:32:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275895038.md)
  - [en](https://longbridge.com/en/news/275895038.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275895038.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275895038.md) | [繁體中文](https://longbridge.com/zh-HK/news/275895038.md)


# Immunic raises USD 200 million in private placement, with potential for up to USD 200 million more. Funds to support Phase 3 trials and transition to commercial-stage company.

An initial sum of $200 million has been received upfront, with the possibility of an additional $200 million in proceeds. This funding is anticipated to cover the costs associated with finalizing the Phase 3 ENSURE trials for relapsing multiple sclerosis, commencing the Phase 3 trial for primary progressive multiple sclerosis, and facilitating the transition into the next phase of the project.

### Related Stocks

- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Immunic, Inc. (IMUX.US)](https://longbridge.com/en/quote/IMUX.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)

## Related News & Research

- [Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium | IMUX Stock News](https://longbridge.com/en/news/278536359.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md)
- [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/en/news/278917368.md)
- [BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress](https://longbridge.com/en/news/278878197.md)
- [Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic Dermatitis](https://longbridge.com/en/news/278448836.md)